A STUDY EVALUATING SAFETY AND EFFICACY OF THE ADDITION OF VELIPARIB PLUS CARBOPLATIN VERSUS THE ADDITION OF CARBOPLATIN TO STANDARD CHEMOTHERAPY VERSUS STANDARD CHEMOTHERAPY IN SUBJECTS WITH EARLY STAGE TRIPLE NEGATIVE BREAST CANCER: